Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

  • Wang, Yifan
  • Bernhardy, Andrea J.
  • Nacson, Joseph
  • Krais, John J.
  • Tan, Yin-Fei
  • Nicolas, Emmanuelle
  • Llop Guevara, Alba
  • Balmaña Gelpí, Judith
  • Serra Elizalde, Violeta
Resistència terapèutica contra el càncer; Càncer d'ovaris, Resistencia terapéutica al cáncer; Cáncer de ovarios, Cancer therapeutic resistance; Ovarian cancer, BRCA1 mutant carcinomas are sensitive to PARP inhibitor (PARPi) therapy; however, resistance arises. BRCA1 BRCT domain mutant proteins do not fold correctly and are subject to proteasomal degradation, resulting in PARPi sensitivity. In this study, we show that cell lines and patient-derived tumors, with highly disruptive BRCT domain mutations, have readily detectable BRCA1 protein expression, and are able to proliferate in the presence of PARPi. Peptide analyses reveal that chemo-resistant cancers contain residues encoded by BRCA1 intron 15. Mechanistically, cancers with BRCT domain mutations harbor BRCA1 gene breakpoints within or adjacent to Alu elements in intron 15; producing partial gene duplications, inversions and translocations, and terminating transcription prior to the mutation-containing BRCT domain. BRCA1 BRCT domain-deficient protein isoforms avoid mutation-induced proteasomal degradation, support homology-dependent DNA repair, and promote PARPi resistance. Taken together, Alu-mediated BRCA1 gene rearrangements are responsible for generating hypomorphic proteins, and may represent a biomarker of PARPi resistance., This work was supported by the US National Institutes of Health (NIH) Grants P50 CA083638 and 5P30 CA006927, as well as R01CA214799, Susan Komen CCRCR17499048, and OC130212 Department of Defense to N.J., and a Pilot Award and Nested Teal Postdoctoral Scholar supported Y.W. (OC140040). We thank Drs. Judith Balmaña, Cristina Saura and Joaquin Arribas for providing materials. PDXs were established thanks to the GHD-Pink program, the FERO Foundation and the Catalan Agency AGAUR [2017 SGR 540]. V.S. is supported by the Instituto de Salud Carlos III (CP14/00228) and ALG by a PERIS fellowship from the Departament de Salut, Generalitat de Catalunya (SLT002/16/00477). Clovis Oncology supplied rucaparib. We are grateful to FCCC Genomics, Cell Culture and Cell Sorting facilities. We thank Hsin Yao Tang at the Wistar Proteomics facility for help with mass spectrometry.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel
  • Palafox Sánchez, Marta
  • Scaltriti, Maurizio
  • Razavi, Pedram
  • Arribas López, Joaquin Vicente
  • Serra Elizalde, Violeta
  • Gris Oliver, Albert
  • Bellet Ezquerra, Meritxell
Biomarcadores de respuesta a fármacos; Redes de co-ocurrencia de conductores; Oncología de precisión, Biomarcadors de resposta a fàrmacs; Xarxes de co-ocurrència de conductors; Oncologia de precisió, Drug-response biomarkers; Driver co-occurrence networks; Precision oncology, Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients’ progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling., L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the Generalitat de Catalunya (VEIS 001-P-001). V.S. is a recipient of a Miguel Servet grant from ISCIII (CPII19/00033) and receives funds from AGAUR (2017 SGR 540). The PDX program is supported by a GHD-Pink (FERO foundation) grant to V.S., A.G.-O. and M.P. received a FI-AGAUR and a Juan de la Cierva (MJCI-2015-25412) fellowship, respectively. M.S., P.R., and S.C. acknowledge the support of the NIH grants P30 CA008748, RO1CA190642, and the Breast Cancer Research Foundation. Additionally, P.R. receives funds from the Breast Cancer Alliance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ibrahim, Yasir Hussein
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Bonache, Sandra|||0000-0002-7395-8143
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Rueda, Oscar M.
  • Lai, Zhongwu|||0000-0002-1506-8222
  • Polanska, Urszula|||0000-0003-1017-594X
  • Jones, Gemma|||0000-0002-7567-681X
  • Kristel, Petra
  • de Bustos, L.
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Montalban, Gemma|||0000-0002-6958-4759
  • Caratù, Ginevra|||0000-0003-1085-8062
  • Mancuso, Francesco M.|||0000-0001-5499-6630
  • Fasani, Roberta|||0000-0003-1630-9988
  • Jiménez, Jose|||0000-0002-2576-1776
  • Howat, William J.
  • Dougherty, Brian|||0000-0002-0093-1142
  • Vivancos, Ana|||0000-0003-2888-6512
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Rubio Rodríguez, Isabel Teresa
  • Oaknin, Ana|||0000-0002-3592-7194
  • Cadogan, Elaine|||0000-0002-9757-8305
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Caldas, Carlos|||0000-0003-3547-1489
  • Baselga Torres, Josep
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Jonkers, Jos|||0000-0002-9264-9792
  • Diez, Orland|||0000-0001-7339-0570
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers has been recently confirmed in clinical trials. Numerous mechanisms of PARPi resistance have been described, whose clinical relevance in gBRCA-mutated breast cancer is unknown. This highlights the need to identify functional biomarkers to better predict PARPi sensitivity. We investigated the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differential response to PARPi. Analysis included exome sequencing and immunostaining of DNA damage response proteins to functionally evaluate HRR. Findings were validated in a retrospective sample set from gBRCA1/2-cancer patients treated with PARPi. RAD51 nuclear foci, a surrogate marker of HRR functionality, were the only common feature in PDX and patient samples with primary or acquired PARPi resistance. Consistently, low RAD51 was associated with objective response to PARPi. Evaluation of the RAD51 biomarker in untreated tumors was feasible due to endogenous DNA damage. In PARPi-resistant gBRCA1 PDXs, genetic analysis found no in-frame secondary mutations, but BRCA1 hypomorphic proteins in 60% of the models, TP53BP1 -loss in 20% and RAD51 -amplification in one sample, none mutually exclusive. Conversely, one of three PARPi-resistant gBRCA2 tumors displayed BRCA2 restoration by exome sequencing. In PDXs, PARPi resistance could be reverted upon combination of a PARPi with an ataxia-telangiectasia mutated (ATM) inhibitor. Detection of RAD51 foci in gBRCA tumors correlates with PARPi resistance regardless of the underlying mechanism restoring HRR function. This is a promising biomarker to be used in the clinic to better select patients for PARPi therapy. Our study also supports the clinical development of PARPi combinations such as those with ATM inhibitors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Palafox, Marta|||0000-0002-1762-3250
  • Scaltriti, Maurizio|||0000-0002-5522-1447
  • Razavi, Pedram
  • Chandarlapaty, Sarat
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Bellet Ezquerra, Meritxell|||0000-0001-8859-8307
  • Serra, Violeta|||0000-0001-6620-1065
  • Aloy, Patrick|||0000-0002-3557-0236
Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients' progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A RAD51 assay feasible in routine tumor samples calls inhibitor response beyond BRCA mutation

  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Ducy, Mandy
  • Ibrahim, Yasir Hussein
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Pellegrino, Benedetta
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Bonache, Sandra|||0000-0002-7395-8143
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Gómez Pardo, Patricia
  • Vidal, Marc
  • Peg, Vicente|||0000-0002-5203-6166
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Dellaire, Graham
  • Simard, Jacques|||0000-0001-6906-3390
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Rubio, Isabel T.|||0000-0003-0035-0679
  • Dientsmann, Rodrigo
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Caldas, Carlos|||0000-0003-3547-1489
  • Baselga Torres, Josep
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Déas, Olivier
  • Jonkers, Jos|||0000-0002-9264-9792
  • Masson, Jean-Yves
  • Cairo, Stefano
  • Judde, Jean-Gabriel
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
Poly(-ribose) polymerase () inhibitors (i) are effective in cancers with defective homologous recombination repair (), including 1/2-related cancers. A test to identify additional -deficient tumors will help to extend their use in new indications. We evaluated the activity of the i olaparib in patient-derived tumor xenografts (s) from breast cancer () patients and investigated mechanisms of sensitivity through exome sequencing, 1 promoter methylation analysis, and immunostaining of proteins, including 51 nuclear foci. In an independent panel, the predictive capacity of the 51 score and the homologous recombination deficiency () score were compared. To examine the clinical feasibility of the 51 assay, we scored archival breast tumor samples, including 2-related hereditary cancers. The 51 score was highly discriminative of i sensitivity versus PARPi resistance in s and outperformed the genomic test. In clinical samples, all 2-related tumors were classified as -deficient by the 51 score. The functional biomarker 51 enables the identification of i-sensitive and broadens the population who may benefit from this therapy beyond 1/2-related cancers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

  • Wang, Yifan
  • Bernhardy, Andrea J.
  • Nacson, Joseph
  • Krais, John J.
  • Tan, Yin-Fei
  • Nicolas, Emmanuelle
  • Llop Guevara, Alba
  • Balmaña Gelpí, Judith
  • Serra Elizalde, Violeta
Resistència terapèutica contra el càncer; Càncer d'ovaris, Resistencia terapéutica al cáncer; Cáncer de ovarios, Cancer therapeutic resistance; Ovarian cancer, BRCA1 mutant carcinomas are sensitive to PARP inhibitor (PARPi) therapy; however, resistance arises. BRCA1 BRCT domain mutant proteins do not fold correctly and are subject to proteasomal degradation, resulting in PARPi sensitivity. In this study, we show that cell lines and patient-derived tumors, with highly disruptive BRCT domain mutations, have readily detectable BRCA1 protein expression, and are able to proliferate in the presence of PARPi. Peptide analyses reveal that chemo-resistant cancers contain residues encoded by BRCA1 intron 15. Mechanistically, cancers with BRCT domain mutations harbor BRCA1 gene breakpoints within or adjacent to Alu elements in intron 15; producing partial gene duplications, inversions and translocations, and terminating transcription prior to the mutation-containing BRCT domain. BRCA1 BRCT domain-deficient protein isoforms avoid mutation-induced proteasomal degradation, support homology-dependent DNA repair, and promote PARPi resistance. Taken together, Alu-mediated BRCA1 gene rearrangements are responsible for generating hypomorphic proteins, and may represent a biomarker of PARPi resistance., This work was supported by the US National Institutes of Health (NIH) Grants P50 CA083638 and 5P30 CA006927, as well as R01CA214799, Susan Komen CCRCR17499048, and OC130212 Department of Defense to N.J., and a Pilot Award and Nested Teal Postdoctoral Scholar supported Y.W. (OC140040). We thank Drs. Judith Balmaña, Cristina Saura and Joaquin Arribas for providing materials. PDXs were established thanks to the GHD-Pink program, the FERO Foundation and the Catalan Agency AGAUR [2017 SGR 540]. V.S. is supported by the Instituto de Salud Carlos III (CP14/00228) and ALG by a PERIS fellowship from the Departament de Salut, Generalitat de Catalunya (SLT002/16/00477). Clovis Oncology supplied rucaparib. We are grateful to FCCC Genomics, Cell Culture and Cell Sorting facilities. We thank Hsin Yao Tang at the Wistar Proteomics facility for help with mass spectrometry.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel
  • Palafox Sánchez, Marta
  • Scaltriti, Maurizio
  • Razavi, Pedram
  • Arribas López, Joaquin Vicente
  • Serra Elizalde, Violeta
  • Gris Oliver, Albert
  • Bellet Ezquerra, Meritxell
Biomarcadores de respuesta a fármacos; Redes de co-ocurrencia de conductores; Oncología de precisión, Biomarcadors de resposta a fàrmacs; Xarxes de co-ocurrència de conductors; Oncologia de precisió, Drug-response biomarkers; Driver co-occurrence networks; Precision oncology, Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients’ progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling., L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the Generalitat de Catalunya (VEIS 001-P-001). V.S. is a recipient of a Miguel Servet grant from ISCIII (CPII19/00033) and receives funds from AGAUR (2017 SGR 540). The PDX program is supported by a GHD-Pink (FERO foundation) grant to V.S., A.G.-O. and M.P. received a FI-AGAUR and a Juan de la Cierva (MJCI-2015-25412) fellowship, respectively. M.S., P.R., and S.C. acknowledge the support of the NIH grants P30 CA008748, RO1CA190642, and the Breast Cancer Research Foundation. Additionally, P.R. receives funds from the Breast Cancer Alliance.